

Early-stage lung cancer is driven by a transitional cell state dependent on a KRAS-ITGA3-SRC axis

Aaron Moyer, Antonella Dost, Robert Ietswaart, Shreoshi Sengupta, VanNashlee Ya, Chrystal Aluya, Caroline Fahey, Sharon Louie, Margherita Paschini, and Carla Kim

Corresponding author: Carla Kim (carla.kim@childrens.harvard.edu)

Review Timeline:

Submission Date:	29th Feb 24
Editorial Decision:	1st Mar 24
Revision Received:	22nd Mar 24
Editorial Decision:	28th Mar 24
Revision Received:	4th Apr 24
Accepted:	17th Apr 24

Editor: Kelly Anderson

Transaction Report:

(Note: Please note that the manuscript was previously reviewed at another journal and the reports were taken into account in the decision making process at The EMBO Journal. Since the original reviews are not subject to EMBO Press' transparent review process policy, the reports and author response cannot be published. With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. Depending on transfer agreements, referee reports obtained elsewhere may or may not be included in this compilation. Referee reports are anonymous unless the Referee chooses to sign their reports.)

Dear Dr. Kim,

Thank you for submitting your manuscript for consideration by the EMBO Journal.

As discussed via zoom, please add the final experimental data and update the references and discussion to include the recently published literature in your revised version.

Thank you for the opportunity to consider your work for publication. I look forward to your revision.

Yours sincerely,

Kelly M Anderson, PhD
Editor, The EMBO Journal
k.anderson@embojournal.org

Instructions for preparing your revised manuscript:

Please make sure you upload a letter of response to the referees' comments together with the revised manuscript.

Please also check that the title and abstract of the manuscript are brief, yet explicit, even to non-specialists.

When assembling figures, please refer to our figure preparation guideline in order to ensure proper formatting and readability in print as well as on screen:

<https://bit.ly/EMBOPressFigurePreparationGuideline>

See also guidelines for figure legends: <https://www.embopress.org/page/journal/14602075/authorguide#figureformat>

At EMBO Press we ask authors to provide source data for the main manuscript figures. Our source data coordinator will contact you to discuss which figure panels we would need source data for and will also provide you with helpful tips on how to upload and organize the files.

IMPORTANT: When you send the revision we will require

- a point-by-point response to the referees' comments, with a detailed description of the changes made (as a word file).
- a word file of the manuscript text.
- individual production quality figure files (one file per figure)
- a complete author checklist, which you can download from our author guidelines (<https://www.embopress.org/page/journal/14602075/authorguide>).
- Expanded View files (replacing Supplementary Information)

Please see out instructions to authors

<https://www.embopress.org/page/journal/14602075/authorguide#expandedview>

Please remember: Digital image enhancement is acceptable practice, as long as it accurately represents the original data and conforms to community standards. If a figure has been subjected to significant electronic manipulation, this must be noted in the figure legend or in the 'Materials and Methods' section. The editors reserve the right to request original versions of figures and the original images that were used to assemble the figure.

Further information is available in our Guide For Authors: <https://www.embopress.org/page/journal/14602075/authorguide>

The authors addressed the remaining issues.

Dear Carla,

Congratulations on a great revision! Please attend to the following editorial items and add this as a point by point so that we can move forward with your manuscript:

1. Please include a title page, the abstract and introduction should begin on the next page.
2. Please add up to five keywords, which may or may not appear in the title, should be given in alphabetical order, below the abstract, each separated by a slash (/).
3. Please update the reference format: should be in alphabetical order and et al is needed after 10 author names.
4. Please rename the conflict of interest statement to: "Disclosure Statement and Competing Interest". Please also include the following sentence: Carla Kim is a member of the advisory Editorial Board of The EMBO Journal. This has no bearing on the editorial consideration of this article for publication.
5. Please provide the figures separately as production quality files rather than one PDF.
6. Please rename tables 1-5 to Datasets EvV1-EV5 and upload as datasets. Please also update the callouts to these datasets in the main manuscript accordingly.
7. We include a synopsis of the paper (see <http://emboj.embopress.org/>). Please provide me with a general summary statement and 3-5 bullet points that capture the key findings of the paper.
8. We also need a summary figure for the synopsis. The size should be 550 wide by 200-440 high (pixels). You can also use something from the figures if that is easier.
9. Please ensure the manuscript sections are in the following order: Title page - Abstract & Keywords - Introduction - Results - Discussion - Methods - Data Availability - Acknowledgments - Disclosure Statement & Competing Interests - References - Figure Legends - Tables with legends - Expanded View Figure Legends.
10. Please rename supplemental figures to Figure EV1-EV5 and update the figure legends and callouts in the main manuscript.
11. As discussed via email, please update the figure legends as needed to clarify when any images are used in multiple panels.
12. Please provide the specific URL and reviewer access code for GSE253461 dataset in the Data Availability statement
13. Please provide the accession ID for the NCBI sequencing read archive database in the DAS
14. Please indicate the statistical test used for data analysis in the legends of Fig4e and 4h.
15. In Figure 4h there is a mismatch between the annotated p values in the figure legend and the annotated p values in the figure file.
16. Please add N information to figures 1f, 2d, 2f, 3d, 4e, S2b, S2c, S3b, S5b.
17. Please define the error bars in the legend of figure 4e.
18. Please add a scale bar and its definition to figure 3a.

Thank you for the opportunity to consider your work for publication. I look forward to your revision.

Yours sincerely,

Kelly M Anderson, PhD
Editor, The EMBO Journal
k.anderson@embojournal.org

Please see out instructions to authors

<https://www.embopress.org/page/journal/14602075/authorguide#expandedview>

Further information is available in our Guide For Authors: <https://www.embopress.org/page/journal/14602075/authorguide>

The authors addressed the minor editorial issues.

Dear Carla,

Congratulations on an excellent manuscript, I am pleased to inform you that your manuscript has been accepted in the EMBO Journal. Thank you for your comprehensive response to the referee concerns and for providing detailed source data. It has been a pleasure to work with you to get this to the acceptance stage.

I will begin the final checks on your manuscript before submitting to the publisher. Once at the publisher, it will take about 3 weeks for your manuscript to be published online (although I will ask them to expedite). As a reminder, the entire review process, including referee concerns and your point-by-point response, will be available to readers.

I will be in touch throughout the final editorial process until publication. In the meantime, I hope you find time to celebrate!

Warm wishes,
Kelly

Kelly M Anderson, PhD
Editor, The EMBO Journal
k.anderson@embojournal.org

Your manuscript will be processed for publication by EMBO Press. It will be copy edited and you will receive page proofs prior to publication. Please note that you will be contacted by Springer Nature Author Services to complete licensing and payment information.

You may qualify for financial assistance for your publication charges - either via a Springer Nature fully open access agreement or an EMBO initiative. Check your eligibility: <https://www.embopress.org/page/journal/14602075/authorguide#chargesguide>

Should you be planning a Press Release on your article, please get in contact with embo_production@springernature.com as early as possible in order to coordinate publication and release dates.

EMBO Press Author Checklist

Corresponding Author Name: Carla F Kim
Journal Submitted to: EMBO
Manuscript Number: EMBOJ-2024-117107

USEFUL LINKS FOR COMPLETING THIS FORM

[The EMBO Journal - Author Guidelines](#)
[EMBO Reports - Author Guidelines](#)
[Molecular Systems Biology - Author Guidelines](#)
[EMBO Molecular Medicine - Author Guidelines](#)

Reporting Checklist for Life Science Articles (updated January 2022)

This checklist is adapted from Materials Design Analysis Reporting (MDAR) Checklist for Authors. MDAR establishes a minimum set of requirements in transparent reporting in the life sciences (see Statement of Task: [10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). Please follow the journal's guidelines in preparing your manuscript.

Please note that a copy of this checklist will be published alongside your article.

Abridged guidelines for figures

1. Data

The data shown in figures should satisfy the following conditions:

- ☑ the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner.
- ☑ ideally, figure panels should include only measurements that are directly comparable to each other and obtained with the same assay.
- ☑ plots include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates.
- ☑ if $n < 5$, the individual data points from each experiment should be plotted. Any statistical test employed should be justified.
- ☑ Source Data should be included to report the data underlying figures according to the guidelines set out in the authorship guidelines on Data Presentation.

2. Captions

Each figure caption should contain the following information, for each panel where they are relevant:

- ☑ a specification of the experimental system investigated (eg cell line, species name).
- ☑ the assay(s) and method(s) used to carry out the reported observations and measurements.
- ☑ an explicit mention of the biological and chemical entity(ies) that are being measured.
- ☑ an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
- ☑ the exact sample size (n) for each experimental group/condition, given as a number, not a range;
- ☑ a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
- ☑ a statement of how many times the experiment shown was independently replicated in the laboratory.
- ☑ definitions of statistical methods and measures:
 - common tests, such as t-test (please specify whether paired vs. unpaired), simple χ^2 tests, Wilcoxon and Mann-Whitney tests, can be unambiguously identified by name only, but more complex techniques should be described in the methods section;
 - are tests one-sided or two-sided?
 - are there adjustments for multiple comparisons?
 - exact statistical test results, e.g., P values = x but not P values < x;
 - definition of 'center values' as median or average;
 - definition of error bars as s.d. or s.e.m.

Please complete ALL of the questions below.
Select "Not Applicable" only when the requested information is not relevant for your study.

Materials

Newly Created Materials	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
New materials and reagents need to be available; do any restrictions apply?	Not Applicable	
Antibodies	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
For antibodies provide the following information: - Commercial antibodies: RRID (if possible) or supplier name, catalogue number and or/clone number - Non-commercial: RRID or citation	Yes	Materials and methods
DNA and RNA sequences	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Short novel DNA or RNA including primers, probes: provide the sequences.	Not Applicable	
Cell materials	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, and OR RRID.	Yes	Materials and methods
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Yes	Materials and methods
Report if the cell lines were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination.	Not Applicable	
Experimental animals	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Laboratory animals or Model organisms: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID.	Yes	Materials and methods
Animal observed in or captured from the field: Provide species, sex, and age where possible.	Not Applicable	
Please detail housing and husbandry conditions .	Yes	Materials and methods
Plants and microbes	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Plants: provide species and strain, ecotype and cultivar where relevant, unique accession number if available, and source (including location for collected wild specimens).	Not Applicable	
Microbes: provide species and strain, unique accession number if available, and source.	Not Applicable	
Human research participants	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
If collected and within the bounds of privacy constraints report on age, sex and gender or ethnicity for all study participants.	Not Applicable	
Core facilities	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
If your work benefited from core facilities, was their service mentioned in the acknowledgments section?	Yes	Acknowledgments

Design

Study protocol	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
If study protocol has been pre-registered , provide DOI in the manuscript. For clinical trials, provide the trial registration number OR cite DOI.	Not Applicable	
Report the clinical trial registration number (at ClinicalTrials.gov or equivalent), where applicable.	Not Applicable	
Laboratory protocol	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Provide DOI OR other citation details if external detailed step-by-step protocols are available.	Not Applicable	
Experimental study design and statistics	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Include a statement about sample size estimate even if no statistical methods were used.	Yes	Materials and Methods
Were any steps taken to minimize the effects of subjective bias when allocating animals/samples to treatment (e.g. randomization procedure)? If yes, have they been described?	Not Applicable	
Include a statement about blinding even if no blinding was done.	Not Applicable	
Describe inclusion/exclusion criteria if samples or animals were excluded from the analysis. Were the criteria pre-established?	Not Applicable	
If sample or data points were omitted from analysis, report if this was due to attrition or intentional exclusion and provide justification.		
For every figure, are statistical tests justified as appropriate? Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it. Is there an estimate of variation within each group of data? Is the variance similar between the groups that are being statistically compared?	Yes	Figure legend
Sample definition and in-laboratory replication	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
In the figure legends: state number of times the experiment was replicated in laboratory.	Yes	Figure legends
In the figure legends: define whether data describe technical or biological replicates .	Yes	Figure legends

Ethics

Ethics	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Studies involving human participants : State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Not Applicable	
Studies involving human participants : Include a statement confirming that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.	Not Applicable	
Studies involving human participants : For publication of patient photos , include a statement confirming that consent to publish was obtained.	Not Applicable	
Studies involving experimental animals : State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Include a statement of compliance with ethical regulations.	Yes	Materials and Methods
Studies involving specimen and field samples : State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Not Applicable	
Dual Use Research of Concern (DURC)	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Could your study fall under dual use research restrictions? Please check biosecurity documents and list of select agents and toxins (CDC): https://www.selectagents.gov/sat/list.htm .	Not Applicable	
If you used a select agent, is the security level of the lab appropriate and reported in the manuscript?	Not Applicable	
If a study is subject to dual use research of concern regulations, is the name of the authority granting approval and reference number for the regulatory approval provided in the manuscript?	Not Applicable	

Reporting

The MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.

Adherence to community standards	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
State if relevant guidelines or checklists (e.g., ICMJE, MIBBI, ARRIVE, PRISMA) have been followed or provided.	Not Applicable	
For tumor marker prognostic studies , we recommend that you follow the REMARK reporting guidelines (see link list at top right). See author guidelines, under 'Reporting Guidelines'. Please confirm you have followed these guidelines.	Not Applicable	
For phase II and III randomized controlled trials , please refer to the CONSORT flow diagram (see link list at top right) and submit the CONSORT checklist (see link list at top right) with your submission. See author guidelines, under 'Reporting Guidelines'. Please confirm you have submitted this list.	Not Applicable	

Data Availability

Data availability	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Have primary datasets been deposited according to the journal's guidelines (see 'Data Deposition' section) and the respective accession numbers provided in the Data Availability Section?	Yes	Materials and methods
Were human clinical and genomic datasets deposited in a public access-controlled repository in accordance to ethical obligations to the patients and to the applicable consent agreement?	Not Applicable	
Are computational models that are central and integral to a study available without restrictions in a machine-readable form? Were the relevant accession numbers or links provided?	Yes	Materials and methods
If publicly available data were reused, provide the respective data citations in the reference list .	Yes	Materials and methods